Advanced search
Publication Cover
Renal Failure Volume 34, 2012 - Issue 5
Submit an article Journal homepage
1,255
Views
27
CrossRef citations to date
0
Altmetric
Clinical Study

Identification of a Novel Mutation and Prevalence Study for Fabry Disease in Japanese Dialysis Patients

Tomoya NishinoSecond Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
,
Yoko ObataSecond Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan;Medical Education Development Center, Nagasaki University Hospital, Nagasaki, JapanCorrespondence[email protected]
,
Akira FurusuSecond Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
,
Misaki HiroseSecond Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
,
Ken ShinzatoShinzato Clinic, Nagasaki, Japan
,
Kiyoko HattoriDepartment of Pediatrics, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan
,
Kimitoshi NakamuraDepartment of Pediatrics, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan
,
Tadashi MatsumotoDepartment of Nursing, Nagasaki University School of Health Sciences, Nagasaki, Japan
,
Fumio EndoDepartment of Pediatrics, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan
&
Shigeru KohnoSecond Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
 show all
Pages 566-570 | Received 29 Nov 2011, Accepted 20 Feb 2012, Published online: 08 May 2012

REFERENCES

  • Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry’s disease. Ceramide trihexosidase deficiency. N Engl J Med. 1967;276:1163–1167.
  • Sweeley CC, Klionsky B. Fabry’s disease: Classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem. 1963;238:3148–3150.
  • Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriber CR, Beauder AL, Sly WS, ., eds. The Metabolic Bases of Inherited Disease. 8th ed. New York: Mc Graw-Hill; 2001:3733–3774.
  • Nakao S, Takenaka T, Maeda M, . An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288–293.
  • Sakuraba H, Oshima A, Fukuhara Y, . Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet. 1990;47:784–789.
  • von Scheidt W, Eng CM, Fitzmaurice TF, . An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med. 1991;324:395–399.
  • Meroni M, Spisni C, Tazzari S, . Isolated glomerular proteinuria as the only clinical manifestation of Fabry’s disease in an adult male. Nephrol Dial Transplant. 1997;12:221–223.
  • Nakao S, Kodama C, Takenaka T, . Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64:801–807.
  • Sawada K, Mizoguchi K, Hishida A, . Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy. Clin Nephrol. 1996;45:289–294.
  • Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–254.
  • Tanaka M, Ohashi T, Kobayashi M, . Identification of Fabry’s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol. 2005;64:281–287.
  • Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y. Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol. 2005;9:228–232.
  • Linthorst GE, Hollak CE, Korevaar JC, Van Manen JG, Aerts JM, Boeschoten EW. Alpha-galactosidase A deficiency in Dutch patients on dialysis: A critical appraisal of screening for Fabry disease. Nephrol Dial Transplant. 2003;18:1581–1584.
  • Kotanko P, Kramar R, Devrnja D, . Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004;15:1323–1329.
  • Merta M, Reiterova J, Ledvinova J, . A nationwide blood spot screening study for Fabry disease in the Czech Republic hemodialysis patient population. Nephrol Dial Transplant. 2007;22:179–186.
  • Thadhani R, Wolf M, West ML, . Patients with Fabry disease on dialysis in the United States. Kidney Int. 2002;61:249–255.
  • Fujii H, Kono K, Goto S, . Prevalence and cardiovascular features of Japanese hemodialysis patients with Fabry disease. Am J Nephrol. 2009;30:527–535.
  • Eng CM, Guffon N, Wilcox WR, . Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry’s disease. N Engl J Med. 2001;345:9–16.
  • Chamoles NA, Blanco M, Gaggioli D. Fabry disease: Enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001;308:195–196.
  • Nakamura K, Robertson M, Liu G, . Complete heart block and sudden death in mice overexpressing calreticulin. J Clin Invest. 2001;107:1245–1253.
  • Shimotori M, Maruyama H, Nakamura G, . Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone. Hum Mutat. 2008;29:331.
  • Rolfs A, Böttcher T, Zschiesche M, . Prevalence of Fabry disease in patients with cryptogenic stroke: A prospective study. Lancet. 2005;366:1794–1796.
  • Chimenti C, Pieroni M, Morgante E, . Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110:1047–1053.
  • Monserrat L, Gimeno-Blanes JR, Marín F, . Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50:2399–2403.
  • Lee BH, Heo SH, Kim GH, . Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet. 2010;55:512–517.
  • Olivova P, van der Veen K, Cullen E, . Effect of sample collection on α-galactosidase A enzyme activity measurements in dried blood spots on filter paper. Clin Chim Acta. 2009;403:159–162.
  • Eng CM, Germain DP, Banikazemi M, . Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8:539–548.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.